Day Current Ratio from 2010 to 2024
| DAWN Stock | USD 12.70 0.22 1.70% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 12.71770367 | Current Value 22.7 | Quarterly Volatility 5.88129527 |
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 271.7 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.53. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
Day | Current Ratio |
Latest Day One's Current Ratio Growth Pattern
Below is the plot of the Current Ratio of Day One Biopharmaceuticals over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Day One's Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 31.45 X | 10 Years Trend |
|
Current Ratio |
| Timeline |
Day Current Ratio Regression Statistics
| Arithmetic Mean | 16.51 | |
| Geometric Mean | 15.78 | |
| Coefficient Of Variation | 35.62 | |
| Mean Deviation | 4.48 | |
| Median | 13.53 | |
| Standard Deviation | 5.88 | |
| Sample Variance | 34.59 | |
| Range | 20.7082 | |
| R-Value | 0.55 | |
| Mean Square Error | 25.91 | |
| R-Squared | 0.30 | |
| Significance | 0.03 | |
| Slope | 0.73 | |
| Total Sum of Squares | 484.25 |
Day Current Ratio History
About Day One Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Day One income statement, its balance sheet, and the statement of cash flows. Day One investors use historical funamental indicators, such as Day One's Current Ratio, to determine how well the company is positioned to perform in the future. Although Day One investors may use each financial statement separately, they are all related. The changes in Day One's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Day One's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Day One Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Day One. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 12.72 | 22.70 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Day Stock
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:Check out the analysis of Day One Correlation against competitors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Return On Assets (0.43) | Return On Equity (0.70) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.